- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06793397
Et fase 3 -forsøg til vurdering af CYB003 i større depressiv lidelse (EMBRACE)
En effektivitet og sikkerhed, fase III, multicenter, dobbeltblind, randomiseret kontrolleret undersøgelse, der sammenligner 2 aktive doser af CYB003 og placebo hos støtteberettigede deltagere med større depressiv lidelse
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Development
- Telefonnummer: 877-361-4003
- E-mail: clinicaltrialsinfo@cybin.com
Studiesteder
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekruttering
- Royal Prince Alfred Hospital
-
Ledende efterforsker:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australien, 4558
- Rekruttering
- Thompson Brain & Mind Healthcare (TBMH)
-
Ledende efterforsker:
- Adem Can
-
Kontakt:
- Megan Dutton
- Telefonnummer: +61 4160 40977
- E-mail: mdutton@tbmh.org.au
-
Kontakt:
- Kristy Smyth
- Telefonnummer: +61 4324 41227
- E-mail: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekruttering
- Ramsay Clinic
-
Ledende efterforsker:
- Malcolm Hopwood
-
Kontakt:
- Melanie Hurley
- Telefonnummer: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Kontakt:
- Grace Monigatti
- Telefonnummer: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australien, 3053
- Rekruttering
- Neurocentrix Research
-
Ledende efterforsker:
- David Barton
-
Kontakt:
- Mai-Anh Bui
- Telefonnummer: +61 3 9546 0009
- E-mail: mai@neurocentrix.com.au
-
Kontakt:
- Gabriela Gonzalez
- Telefonnummer: +61 3 9959 8375
- E-mail: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australien, 3168
- Rekruttering
- Monash University - Notting Hill
-
Kontakt:
- Olivia Lavalette
- Telefonnummer: 0426359494
- E-mail: olivia.lavalette@monash.edu
-
Ledende efterforsker:
- Paul Liknaitzky
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB1 2EU
- Rekruttering
- Cambridge University Hospital NHS
-
Ledende efterforsker:
- Liliana Galindo
-
Kontakt:
- Tracy Assari
- Telefonnummer: +44 1223 219751
- E-mail: t.assari@nhs.net
-
Kontakt:
- Emma Tudor
- Telefonnummer: +44 1223 219751
- E-mail: Emma.tudor@cpft.nhs
-
Doncaster, Det Forenede Kongerige, DN4 8QN
- Rekruttering
- Clerkenwell Health - Doncaster
-
Ledende efterforsker:
- Paul Morrison
-
Kontakt:
- Celia Creaghan
- Telefonnummer: +44 7849 640886
- E-mail: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Det Forenede Kongerige, EH16 4TJ
- Ikke rekrutterer endnu
- NHS Research Scotland
-
Ledende efterforsker:
- Donald MacIntyre
-
Kontakt:
- Carrie Wardhaugh
- Telefonnummer: +44 1315375867
- E-mail: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Det Forenede Kongerige, G51 4TF
- Ikke rekrutterer endnu
- Queen Elizabeth University Hospital
-
Ledende efterforsker:
- Maytal Wolfe
-
Kontakt:
- Rebecca Baird
- E-mail: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Det Forenede Kongerige, L7 8XP
- Ikke rekrutterer endnu
- Royal Liverpool Hospital
-
Kontakt:
- Rachel Crick
- Telefonnummer: +44730 861 3597
- E-mail: Rachel.Crick@merseycare.nhs.uk
-
Ledende efterforsker:
- Fabian Devlin
-
London, Det Forenede Kongerige, EC2Y 8EA
- Rekruttering
- St Pancras Clinical Research
-
Ledende efterforsker:
- Martin Johnson
-
Kontakt:
- Participant Engagement Team
- Telefonnummer: +44 20 38651142
- E-mail: studyinformation@stpancrasclinical.com
-
London, Det Forenede Kongerige, W1U 6RP
- Rekruttering
- Clerkenwell Health - Baker Street
-
Ledende efterforsker:
- Alishah Suleman
-
Kontakt:
- Takunda Gwenhure
- Telefonnummer: +44 2038974867
- E-mail: tgwenhure@clerkenwellhealth.com
-
Kontakt:
- Victor Jardim
- Telefonnummer: +44 2038974867
- E-mail: vjardim@clerkenwellhealth.com
-
London, Det Forenede Kongerige, W1G9 RU
- Rekruttering
- Re:Cognition Health
-
Ledende efterforsker:
- Dimitrios Paschos
-
Kontakt:
- Telefonnummer: +44-0800-802-1030
-
London, Det Forenede Kongerige, SE5 9RS
- Rekruttering
- King's College London
-
Kontakt:
- Catheine Bird
- E-mail: catherine.bird@kcl.ac.uk
-
Kontakt:
- Paige Seath
- E-mail: paige.seath@kcl.ac.uk
-
Ledende efterforsker:
- James Rucker
-
London, Det Forenede Kongerige, W1G 8DR
- Trukket tilbage
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Det Forenede Kongerige, NE4 5PL
- Rekruttering
- Edwardson Building - Campus for Ageing and Vitality
-
Kontakt:
- Victoria Wilson
- Telefonnummer: +44 191 246 8647
- E-mail: victoria.wilson3@cntw.nhs.uk
-
Kontakt:
- Rebecca Woodhouse
- E-mail: Rebecca.Woodhouse@cntw.nhs.uk
-
Ledende efterforsker:
- Mourad Wahba
-
Reading, Det Forenede Kongerige, RG7 8PA
- Rekruttering
- Ascend Clinical Research
-
Ledende efterforsker:
- Pamela Walters
-
Kontakt:
- Alexandra Diaz
- Telefonnummer: +44 118 3045905
- E-mail: adiaz@ascendclinical-research.com
-
Sheffield, Det Forenede Kongerige, S4 7QQ
- Rekruttering
- Sheffield Health and Social Care NHS Foundation Trust
-
Ledende efterforsker:
- William Gann
-
Kontakt:
- Mishell Cunningham
- Telefonnummer: +44 114 271 6731
- E-mail: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- Rekruttering
- UAB Psychiatry and Behavioral Neurology
-
Kontakt:
- Seher Premani
- Telefonnummer: 205-996-1198
- E-mail: spremani@uab.edu
-
Ledende efterforsker:
- Peter Hendricks
-
Kontakt:
- Maggie Gossage
- E-mail: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Lighthouse Psychiatry
-
Kontakt:
- Chung Trinh
- Telefonnummer: 435-268-5800
- E-mail: ctrinh@neosciclinicalresearch.com
-
Ledende efterforsker:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72204
- Trukket tilbage
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Forenede Stater, 91206
- Rekruttering
- Behavioral Research Specialists, LLC
-
Ledende efterforsker:
- Jesse Carr
-
Kontakt:
- Laisha Uribe
- Telefonnummer: 888-255-5798
- E-mail: laisha@brstrials.com
-
Imperial, California, Forenede Stater, 92251
- Trukket tilbage
- Sun Valley Research Center
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- CalNeuro Research Group
-
Ledende efterforsker:
- Alexander Bystritsky
-
Kontakt:
- Telefonnummer: 310-208-7144
- E-mail: info@calneuroresearch.com
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- Lipov Medical Group
-
Kontakt:
- Brittany Juhlmann
- Telefonnummer: 262-352-8835
- E-mail: brittany.juhlmann@stellacenter.com
-
Ledende efterforsker:
- Jacob Moussai
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- NRC Research Institute
-
Kontakt:
- Christian Ortiz
- Telefonnummer: 714-289-1100
- E-mail: cortiz@nrcresearch.com
-
Ledende efterforsker:
- Daniel Chueh
-
Orange, California, Forenede Stater, 92866
- Rekruttering
- ATP Clinical Research
-
Ledende efterforsker:
- Gustavo Alva
-
Kontakt:
- Sarah Perkins
- Telefonnummer: 949-354-5353
- E-mail: sarahp@pnsoc.com
-
San Juan Capistrano, California, Forenede Stater, 92675
- Ikke rekrutterer endnu
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Ledende efterforsker:
- Neelima Kunam
-
Kontakt:
- Telefonnummer: 909-955-5865
- E-mail: research@inlandpsych.com
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- Psychedelic Science Institute
-
Ledende efterforsker:
- Keith Heinzerling
-
Kontakt:
- Telefonnummer: 213-973-7512
- E-mail: trialadmin@psychedelicsci.com
-
Stanford, California, Forenede Stater, 94305
- Trukket tilbage
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06511
- Rekruttering
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Ledende efterforsker:
- Ben Kelmendi
-
Kontakt:
- Daidre Chamberlain
- Telefonnummer: 203-693-1591
- E-mail: enact@yale.edu
-
Kontakt:
- Terrence Ching
- Telefonnummer: 502-612-1127
- E-mail: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32256
- Rekruttering
- CNS Healthcare
-
Kontakt:
- Telefonnummer: 904-281-5757
-
Ledende efterforsker:
- John Mark Joyce
-
Maitland, Florida, Forenede Stater, 32751
- Rekruttering
- Accel Research Sites - Maitland
-
Kontakt:
- Telefonnummer: 407-644-1165
-
Ledende efterforsker:
- Andrea Marrafino
-
Naples, Florida, Forenede Stater, 34105
- Rekruttering
- Aqualane Clinical Research
-
Ledende efterforsker:
- Matthew Baker
-
Kontakt:
- Rachel Novella
- Telefonnummer: 239-529-6780
- E-mail: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Forenede Stater, 33634
- Rekruttering
- K2 Medical Research Tampa
-
Ledende efterforsker:
- Kelley Wilson
-
Kontakt:
- Jessica Myers
- Telefonnummer: 352-500-5252
- E-mail: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Trukket tilbage
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Psych Atlanta
-
Ledende efterforsker:
- Michael Banov
-
Kontakt:
- Telefonnummer: 770-422-2846
- E-mail: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- Rush University
-
Ledende efterforsker:
- Joshua Eloge
-
Kontakt:
- Stephanie Gutierrez
- Telefonnummer: 312-942-8995
- E-mail: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Forenede Stater, 70006
- Trukket tilbage
- Tandem Clinical Research
-
New Orleans, Louisiana, Forenede Stater, 70115
- Rekruttering
- Atlas Psychiatry
-
Kontakt:
- Milton Boresoff
- Telefonnummer: 504-899-1682
- E-mail: m.boresoff@atlaspsychiatry.com
-
Ledende efterforsker:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21224
- Trukket tilbage
- Johns Hopkins Medicine
-
Rockville, Maryland, Forenede Stater, 20850
- Ikke rekrutterer endnu
- Sunstone Medical, PC
-
Kontakt:
- Manish Agrawal, MD
- Telefonnummer: 301-750-3401
- E-mail: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02116
- Rekruttering
- Adams Clinical Boston
-
Ledende efterforsker:
- Darin Dougherty
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-mail: info@adamsclinical.com
-
Watertown, Massachusetts, Forenede Stater, 02472
- Rekruttering
- Adams Clinical Watertown
-
Ledende efterforsker:
- Stephanie Ellickson
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-mail: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Forenede Stater, 55347
- Rekruttering
- Institute for Integrative Therapies
-
Ledende efterforsker:
- Manoj Doss
-
Kontakt:
- Sena Ostwalt
- Telefonnummer: 6512808774
- E-mail: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Forenede Stater, 55427
- Ikke rekrutterer endnu
- The Remedy Mental Health
-
Kontakt:
- Emmanuel Arhin
- Telefonnummer: (651) 382-9518
- E-mail: emmanuel.arhin@theremedymn.com
-
Ledende efterforsker:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89119
- Rekruttering
- Redbird Research, LLC
-
Ledende efterforsker:
- Jelena Kunovac
-
Kontakt:
- Telefonnummer: 702-577-2000
- E-mail: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Rekruttering
- Bio Behavioral Health
-
Kontakt:
- Jessica Sutton
- Telefonnummer: 732-244-2299
- E-mail: jessica@bbhnj.com
-
Ledende efterforsker:
- Ashok Patel
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Ikke rekrutterer endnu
- New York State Psychiatric Institute
-
Ledende efterforsker:
- Natalie Gukasyan
-
Kontakt:
- Alexandra Mackay
- Telefonnummer: 212-342-1424
- E-mail: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Adams Clinical Harlem
-
Ledende efterforsker:
- Rachel Noone
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-mail: info@adamsclinical.com
-
The Bronx, New York, Forenede Stater, 10461
- Rekruttering
- Adams Clinical Bronx
-
Ledende efterforsker:
- Shama Farooq
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-mail: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73112
- Trukket tilbage
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Adams Clinical Philadelphia
-
Ledende efterforsker:
- Cassie Blanchard
-
Kontakt:
- Participant Navigators
- Telefonnummer: 267-376-0266
- E-mail: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Forenede Stater, 19462
- Rekruttering
- Flourish Research Philadelphia
-
Ledende efterforsker:
- Rachna Saralkar
-
Kontakt:
- Telefonnummer: 215-614-5606
-
-
Texas
-
Austin, Texas, Forenede Stater, 78737
- Trukket tilbage
- Austin Clinical Trial Partners
-
DeSoto, Texas, Forenede Stater, 75115
- Rekruttering
- Adams Clinical Dallas
-
Ledende efterforsker:
- Rajinder Shiwach
-
Kontakt:
- Participant Navigators
- Telefonnummer: 469-379-2494
- E-mail: info@adamsclinical.com
-
Fort Worth, Texas, Forenede Stater, 76104
- Trukket tilbage
- North Texas Clinical Trials
-
Houston, Texas, Forenede Stater, 77046
- Rekruttering
- Brain Health Consultants and TMS Center
-
Ledende efterforsker:
- Lauren Marangell
-
Kontakt:
- Telefonnummer: 713-489-5000
- E-mail: info@brainhealthconsultants.com
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Flourish Research San Antonio
-
Ledende efterforsker:
- Parke Hedges
-
Kontakt:
- Xavier Martinez
- Telefonnummer: 237 210-949-0122
- E-mail: xmartinez@flourishresearch.com
-
Kontakt:
- Andrea Gomez
- Telefonnummer: 122 210-949-0122
- E-mail: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Forenede Stater, 98201
- Ikke rekrutterer endnu
- Core Clinical Research
-
Kontakt:
- Maria Golescu
- Telefonnummer: 425-443-9551
- E-mail: maria.golescu@ccrtrial.com
-
Ledende efterforsker:
- James Knutson
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- Seattle Neuropsychiatric Treatment Center
-
Ledende efterforsker:
- Rebecca Allen
-
Kontakt:
- Telefonnummer: 5 206-467-6300
- E-mail: research@seattlentc.com
-
-
-
-
-
Athens, Grækenland, 12462
- Rekruttering
- Attikon University Hospital
-
Ledende efterforsker:
- Nikolaos Smyrnis
-
Kontakt:
- Thomas Karantinos
- Telefonnummer: +30697466610
- E-mail: tkarantinos@gmail.com
-
Athens, Grækenland, 11528
- Rekruttering
- Eginitio Hospital
-
Ledende efterforsker:
- Nikos Stefanis
-
Kontakt:
- Adam Adamopoulos
- Telefonnummer: +30 6976032181
- E-mail: adam_adamopoulos@yahoo.com
-
Thessaloniki, Grækenland, 56404
- Rekruttering
- Papageorgiou General Hospital
-
Ledende efterforsker:
- Georgios Papazisis
-
Kontakt:
- Ogla Vampertzi
- Telefonnummer: +306973852659
- E-mail: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irland, D24 WK80
- Rekruttering
- Sheaf House - Tallaght Adult Mental Health Service
-
Ledende efterforsker:
- John Kelly
-
Kontakt:
- Ann Connolly
- Telefonnummer: +353 8616 79619
- E-mail: aconnolly@crp.healthcare
-
Galway, Irland, H91 VE03
- Rekruttering
- La Nua Day Hospital Mental Health Centre
-
Kontakt:
- Prathyusha Nedunuru
- Telefonnummer: +353 874283750
- E-mail: pnedunuru@crp.healthcare
-
Ledende efterforsker:
- Shane McInerney
-
-
-
-
-
Bialystok, Polen, 15-272
- Trukket tilbage
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polen, 85-133
- Rekruttering
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Kontakt:
- Franciszek Lauchut
- Telefonnummer: +48 790 219 501
- E-mail: f.lachut@pro-mente.pl
-
Ledende efterforsker:
- Katarzyna Lachut
-
Gdansk, Polen, 80-546
- Rekruttering
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Kontakt:
- Monika Drzewiecka
- Telefonnummer: +48 508-348-938
- E-mail: m.drzewiecka@pihouse.pl
-
Ledende efterforsker:
- Hanna Badzio-Jagiello
-
Gdansk, Polen, 80-214
- Ikke rekrutterer endnu
- UCK
-
Ledende efterforsker:
- Wieslaw Jerzy Cubala
-
Kontakt:
- Natalia Sudol
- Telefonnummer: +48 669 439 740
- E-mail: nat.sudol13@gmail.com
-
Warsaw, Polen, 02-957
- Ikke rekrutterer endnu
- Department of Pharmacology and Physiology of CNS
-
Ledende efterforsker:
- Justyna Holka-Pokorska
-
Warsaw, Polen, 02-172
- Rekruttering
- MTZ Clinical Research Powered by Pratia
-
Ledende efterforsker:
- Monika Gawlowicz
-
-
-
-
-
Prague, Tjekkiet
- Ikke rekrutterer endnu
- Institute of neuropsychiatric Care (INEP)
-
Ledende efterforsker:
- Alexander Nawka
-
Kontakt:
- Telefonnummer: +420 222 201 020
- E-mail: info@inep.cz
-
Prague, Tjekkiet
- Ikke rekrutterer endnu
- Psyon s.r.o.
-
Ledende efterforsker:
- Tomas Palenicek
-
Kontakt:
- Telefonnummer: +420 774 401 161
- E-mail: info@psyon.cz
-
Předměstí, Tjekkiet
- Ikke rekrutterer endnu
- A-SHINE s.r.o.
-
Ledende efterforsker:
- Lubos Janu
-
Kontakt:
- Blanka Vopelková
- Telefonnummer: +490 777 732 244
- E-mail: blanka.vopelkova@seznam.cz
-
-
-
-
-
Berlin, Tyskland, 10117
- Ikke rekrutterer endnu
- Charité Universitaetsmedizin Berlin
-
Ledende efterforsker:
- Michael Koslowski
-
Kontakt:
- Telefonnummer: +49 30 450 617734
- E-mail: psychedelika-studien@charite.de
-
Frankfurt am Main, Tyskland, 60528
- Ikke rekrutterer endnu
- University Hospital Frankfurt
-
Ledende efterforsker:
- Andreas Reif
-
Kontakt:
- Tanja Scharf
- Telefonnummer: +49 69 6301 86078
- E-mail: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Tyskland, 68159
- Ikke rekrutterer endnu
- Central Institute of Mental Health
-
Kontakt:
- Karin Bopp
- Telefonnummer: 3016 +49 621 1703 3163
- E-mail: Karin.bopp@zi-mannheim.de
-
Ledende efterforsker:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66421
- Ikke rekrutterer endnu
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Ledende efterforsker:
- Matthias Riemenschneider
-
Kontakt:
- Christine Geiger
- Telefonnummer: +49 6841 1624227
- E-mail: christine.geiger@uks.eu
-
Kontakt:
- Aline Freer
- Telefonnummer: +49 6841 1614219
- E-mail: aline.freer@uks.eu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Eksperimentel: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Placebo komparator: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Tidsramme: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Tidsramme: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tidsramme: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Felix Mazer, Cybin IRL Limited
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CYB003-003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .